|
Chemical and Drug Induced Liver Injury
|
0.500 |
Therapeutic
|
disease |
RGD |
GC-MS Analysis: In Vivo Hepatoprotective and Antioxidant Activities of the Essential Oil of Achillea biebersteinii Afan. Growing in Saudi Arabia.
|
27293452 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
RGD |
A Chinese herbal medicine, Gexia-Zhuyu Tang (GZT), prevents dimethylnitrosamine-induced liver fibrosis through inhibition of hepatic stellate cells proliferation.
|
22706148 |
2012 |
|
Chemical and Drug Induced Liver Injury
|
0.500 |
Therapeutic
|
disease |
RGD |
Liver protective activity of a hydroethanolic extract of Arrabidaea chica (Humb. and Bonpl.) B. Verl. (pariri).
|
21772750 |
2011 |
|
Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
CTD_human |
Determination of the key innate genes related to individual variation in carbon tetrachloride-induced hepatotoxicity using a pre-biopsy procedure.
|
19481104 |
2009 |
|
Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
RGD |
Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity.
|
19085960 |
2009 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.
|
17072980 |
2006 |
|
Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
CTD_human |
Nephrotoxic and hepatotoxic effects of triclosan and chlorhexidine in rats.
|
145039 |
1977 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TA-allele was associated with only marginally lower ALT in lean nondrinkers with low genetic risk of hepatic steatosis.
|
31155741 |
2020 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Liver function tests (alanine aminotransferase, ALT; gamma-glutamyltransferase, GGT) not always normalize after elimination of hepatitis C virus (HCV) by direct acting antivirals (DAAs), possibly indicating concomitant non-viral liver diseases.
|
31241820 |
2020 |
|
Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We tested the association of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general population, including 497 with cirrhosis and 113 with hepatocellular carcinoma.
|
31155741 |
2020 |
|
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
As a result, the ABCC2 rs3740065 genotype, sex, and the baseline level of alanine aminotransferase are independent risk factors of antituberculosis drug-induced hepatotoxicity, with P values of .008, .014, and <.001, respectively.
|
31648372 |
2020 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with steatosis had significantly higher preoperative fasting insulin (41.4 versus 21.1 mIU/L, p = 0.000), and patients with fibrosis had significantly higher glycated hemoglobin (6.1% versus 5.5%, p = 0.033) and alanine aminotransferase (81.5 versus 52.7 mg/dL, p = 0.043).
|
31446562 |
2020 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TA-allele was associated with only marginally lower ALT in lean nondrinkers with low genetic risk of hepatic steatosis.
|
31155741 |
2020 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hp 2-2 patients treated with VitE versus placebo showed significant histologic improvement (51% vs. 20%; OR=4.2; P=0.006), resolution of steatohepatitis (44% vs. 12%; OR=6.2; P=0.009), decrease in nonalcoholic fatty liver disease Activity Score (NAS) (-2.2 vs. -0.6; P=0.001), and decrease in liver enzymes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase.
|
30586008 |
2020 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
PCA mitigated DEX-induced liver steatosis with associated reduction in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity.
|
31557503 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Predictive Values of Serum Uric Acid and Alanine-aminotransferase for Fatty Liver Index in Montenegrin Population.
|
31496904 |
2019 |
|
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Saroglitazar also improved alanine aminotransferase levels and fatty liver (evaluated by FibroScan™) in non-alcoholic fatty liver disease patients with diabetic dyslipidemia.
|
31208414 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nine to 16 years postpartum, a clinical examination was performed, with measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transferase, from which fatty liver scoring indices were calculated to assess liver fat score, fatty liver index, hepatic steatosis index, and liver fat percentage.
|
31001915 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (γ-GTP), alkaline phosphatase (ALP), and fatty liver index (FLI) at 3 months of treatment; the proportion of patients with abnormal liver function whose liver function normalized after 3 months of treatment; and correlations between changes in ALT levels and efficacy variables/laboratory values.
|
30393249 |
2019 |
|
Fatty Liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The multivariate analysis demonstrated statistical significance only in the association of body mass index (odds ratio [OR] = 1.22; 95% CI 1.05-1.41; P = 0.01); fatty liver (OR = 2.32; 95% CI 1.58-9.19; P = 0.02); alanine transaminase (OR = 1.04; 95% CI 1.02-1.09; P = 0.04) and cumulative MTX dosage (OR = 1.03; 95% CI 1.01-1.04; P = 0.001).
|
30565876 |
2019 |
|
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was a significantly higher mean ALT level in patients with hepatic steatosis (42.2 U/L; 95% CI 38.4-46.0) compared to patients without (28.8 U/L; 95% CI 25.7-31.9) (P < 0.0001).
|
30874372 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The LCPUFAs eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3, DHA) have a positive effect in diminishing liver steatosis, OS, and the levels of aspartate aminotransferase, alanine aminotransferase and pro-inflammatory cytokines, with improvement of insulin sensitivity and adiponectin levels.
|
30968772 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results showed that the toxic effect of INH in zebrafish in an inflammatory state was more obvious than that in normal zebrafish, that liver size was significantly decreased as measured by liver fatty acid binding protein (LFABP) reporter fluorescence and intensity, and that alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly increased.
|
30858204 |
2019 |
|
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combining ALT and US did not result in better accuracy than ALT or US alone.Conclusion: ALT and US have comparable and only moderate diagnostic accuracy for detecting hepatic steatosis in children with obesity.
|
30903305 |
2019 |
|
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The effect on liver function was evaluated by changes in the fatty liver index, and changes in AST and ALT were evaluated in patients with normal and abnormal liver function.
|
30767112 |
2019 |